Ypsomed Holding

Ypsomed Holding is a Swiss multinational medical technology company headquartered in Burgdorf, Switzerland. Its business is centered on drug-delivery systems that enable patients to administer medicines independently, particularly in chronic-care settings. The company develops and manufactures injection devices, infusion systems, insulin pens, auto-injectors and related delivery technologies for pharmaceutical and biotechnology customers as well as for people managing conditions such as diabetes. Ypsomed was established in 2003 in connection with the breakup of the Disetronic Group, a medical-device business founded by Swiss entrepreneur Willy Michel. The company inherited and developed expertise in compact drug-delivery systems, including technologies designed to make self-medication more practical, discreet and reliable. Rather than operating primarily as a consumer pharmaceutical brand, Ypsomed occupies a business-to-business and medical-technology position: its systems may be supplied under the Ypsomed name or incorporated into solutions developed with pharmaceutical and biotechnology partners. Its principal areas include insulin administration and other injectable therapies. Pen systems are intended to support convenient, measured dosing, while infusion pumps and associated systems are designed for continuous or programmed delivery. Auto-injectors address medicines that patients or caregivers need to administer with limited clinical assistance. These product categories reflect broader healthcare trends toward home treatment, patient independence, chronic-disease management and the move of certain therapies away from hospitals and clinics. Ypsomed’s operating model combines device engineering, manufacturing and collaboration with medicine developers. The company’s role can extend from development of a delivery platform to production of devices suitable for commercial pharmaceutical use. This makes design reliability, human factors, dose accuracy, usability and manufacturing scalability central to its competitive proposition. Its focus on self-medication also places the company at the intersection of medical devices, pharmaceutical packaging and connected or user-oriented treatment systems. According to the supplied reference material, Ypsomed employed more than 2,800 people in 2025 and reported annual turnover of CHF 728.9 million for the referenced period. Those figures should be read with their associated reporting period and source context rather than as timeless company metrics. Ypsomed remains an active Swiss listed company and is identified with the development and manufacture of injection and infusion systems for diabetes care, biotechnology and other self-administered therapies.

Ypsomed Holding was founded in 2003 following the breakup of the Disetronic Group, a Swiss medical-device company founded by Willy Michel. The separation created the basis for an independent business focused on drug-delivery technology rather than on pharmaceutical products themselves. From its origin, Ypsomed’s capabilities were associated with devices that allow medicines to be administered outside traditional clinical settings. The company developed around injection and infusion systems used in self-medication. Diabetes care became a central application area because insulin treatment requires dependable, repeatable and increasingly user-friendly delivery methods. Ypsomed’s product scope also extended to auto-injectors and other systems for injectable medicines used in biotechnology and chronic-care treatment. These devices are intended to support patients, caregivers and healthcare professionals by making administration more manageable and reducing dependence on hospital-based procedures. Ypsomed’s business is primarily technology- and manufacturing-led. It designs and produces delivery platforms that can be used for its own branded offerings or in cooperation with pharmaceutical and biotechnology companies. This model requires expertise in mechanical and device engineering, usability, production quality and the integration of delivery systems with specific medicines. As self-administered therapies have become more important, the company’s role has broadened from traditional device production toward solutions designed around patient convenience and long-term treatment routines. The company is headquartered in Burgdorf, Switzerland, and operates as a multinational medical-technology business. Its continued emphasis on injection systems, infusion systems, insulin pens and auto-injectors reflects a strategic concentration on drug delivery rather than a broad medical-equipment portfolio. The company’s products support the wider healthcare shift toward home treatment and self-management of chronic conditions. By 2025, the supplied reference described Ypsomed as employing more than 2,800 people and generating annual turnover of CHF 728.9 million for the relevant reporting period. Ypsomed is listed on the SIX Swiss Exchange. No additional executive history, campaign record, scandal record or corporate transaction is included here because the supplied materials do not provide sufficiently specific and verifiable information for those sections.

• 2025

  Company scale reported

  [1]Ypsomed Holdingen.wikipedia.org

  The supplied reference material describes Ypsomed as employing more than 2,800 people and reporting annual turnover of CHF 728.9 million for the referenced period.

• 2003

  Ypsomed is established

  [1]Ypsomed Holdingen.wikipedia.org

  Ypsomed Holding is founded in connection with the breakup of the Disetronic Group, the medical-device company founded by Willy Michel.

A Swiss medical-technology specialist focused on reliable, patient-oriented drug-delivery systems for self-medication, especially in diabetes care and biotechnology.

• Diabetes drug-delivery devices

  Insulin pens

  Pen-shaped injection devices intended to help people administer measured doses of insulin and manage diabetes treatment outside a clinical setting. They emphasize portability, dosing convenience and routine self-medication.

• Injection devices

  Auto-injectors

  Device platforms designed to simplify administration of injectable medicines. Auto-injectors can support patients or caregivers who need to deliver therapy with limited professional assistance and are relevant to pharmaceutical and biotechnology applications.

• Infusion systems

  Infusion pumps

  Infusion devices for delivering medicines in a controlled manner, including applications associated with diabetes care. They form part of Ypsomed’s broader portfolio of systems for self-medication and chronic-condition management.

• Medical technology platforms

  Drug-delivery systems

  Injection and infusion platforms developed for self-administered pharmaceutical and biotechnology therapies. These systems combine device engineering, usability and manufacturing capabilities for treatment delivered outside hospitals and clinics.

1. 1Ypsomed Holdingen.wikipedia.org